SS Innovations International (NASDAQ: SSII) announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year. The company's SSi Mantra surgical robotic system installations rose 30.4% to 30 during the quarter, contributing to a cumulative installed base of 224 systems across 12 countries as of June 30.
Gross profit increased 20% to $7.1 million, with a gross margin of 50.9%. The company reported a net loss of $2.7 million, or $0.01 per diluted share, compared with a net loss of $0.3 million in the prior-year quarter. For the first half of 2026, revenue surged 65.6% to $25 million, and SSi Mantra installations grew 47.4% to 56.
As of June 30, SS Innovations held $13.6 million in cash and cash equivalents and had no long-term debt. The company has completed 12,272 cumulative procedures using the SSi Mantra, including 175 telesurgeries. Notably, it recently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's remote capabilities.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones could open significant markets, potentially expanding access to affordable robotic surgery globally.
The strong revenue growth and expanding installed base highlight the increasing adoption of SS Innovations' cost-effective surgical robots. By focusing on affordability and accessibility, the company aims to bring robotic surgery to a broader patient population, particularly in regions where such technology has been limited.
For more details, visit the full press release.
